Ligand Pharmaceuticals Incorporated (LGND)

NASDAQ: LGND · IEX Real-Time Price · USD
81.36
-0.07 (-0.09%)
At close: Apr 12, 2024, 4:00 PM
80.52
-0.84 (-1.03%)
After-hours: Apr 12, 2024, 4:03 PM EDT
-0.09%
Market Cap 1.44B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 17.71M
EPS (ttm) 3.03
PE Ratio 26.77
Forward PE 18.14
Dividend n/a
Ex-Dividend Date n/a
Volume 171,376
Open 81.48
Previous Close 81.43
Day's Range 80.43 - 81.73
52-Week Range 49.24 - 94.57
Beta 0.92
Analysts Strong Buy
Price Target 116.33 (+42.98%)
Earnings Date May 2, 2024

About LGND

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 18, 1992
Employees 58
Stock Exchange NASDAQ
Ticker Symbol LGND
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for LGND stock is "Strong Buy." The 12-month stock price forecast is $116.33, which is an increase of 42.98% from the latest price.

Price Target
$116.33
(42.98% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference

LONDON--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on ...

4 days ago - Business Wire

Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™

JUPITER, Fla. & DURHAM, N.C.--(BUSINESS WIRE)--Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of s...

9 days ago - Business Wire

Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a f...

5 weeks ago - Business Wire

Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand's Human Capital Management and Compensation Committee approved the g...

5 weeks ago - Business Wire

Ligand Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forec...

6 weeks ago - Business Wire

Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa®

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japan...

7 weeks ago - Business Wire

Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed Richard Baxter to the role of Senior Vice President of Investment Operations, and Karen ...

2 months ago - Business Wire

Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report full year and fourth quarter 2023 financial results before the opening of the U.S. fi...

2 months ago - Business Wire

Iambic Therapeutics Announces New Research Published in Nature Machine Intelligence Demonstrating the Capabilities of Its Generative AI NeuralPLexer Technology to Predict Protein-Ligand Complex Structures

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, today announced the publication of research in...

2 months ago - Business Wire

Ligand Pharma's at-home skin treatment gets FDA approval

Ligand Pharmaceuticals' topical treatment for a viral skin infection has received approval from the U.S. health regulator, the company said on Friday, marking the first-ever at-home approved treatment...

3 months ago - Reuters

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) f...

3 months ago - Business Wire

20 favorite small-cap stocks for 2024 among Wall Street analysts

The 2023 stock-market rally has been led by the “Magnificent Seven” companies, which have driven an accelerating upward trend for the large-cap benchmark S&P 500. Shares of smaller and medium-sized co...

3 months ago - Market Watch

Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) hosted an Investor and Analyst Day in New York City earlier today. CEO Todd Davis and other members of Ligand's senior ma...

4 months ago - Business Wire

Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host its Investor and Analyst Day on Tuesday, December 12, 2023. Members of Ligand's senior management team will pro...

4 months ago - Business Wire

Ligand Reports Third Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)---- $LGND #earnings--Ligand reports third quarter 2023 financial results.

5 months ago - Business Wire

Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million

SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Royalty on Sanofi's TZIELD® for $20 Million.

Other symbols: SNY
5 months ago - Business Wire

Ligand To Report Third Quarter 2023 Financial Results On November 8

SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand To Report Third Quarter 2023 Financial Results On November 8.

6 months ago - Business Wire

Ligand Acquires Assets of Novan, Inc. for $12.2 Million

SAN DIEGO--(BUSINESS WIRE)--Ligand Acquires Assets of Novan, Inc. for $12.2 Million.

7 months ago - Business Wire

Ligand Appoints Martine Zimmermann to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Ligand Appoints Martine Zimmermann to its Board of Directors.

7 months ago - Business Wire

Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

SAN DIEGO--(BUSINESS WIRE)--Ligand's Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze.

Other symbols: JAZZ
7 months ago - Business Wire

Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control

SAN DIEGO--(BUSINESS WIRE)--Ligand's Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI.

7 months ago - Business Wire

Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio

SAN DIEGO--(BUSINESS WIRE)--Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio.

7 months ago - Business Wire

Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Ligand Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4).

7 months ago - Business Wire

Ligand Reports Second Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand Reports Second Quarter 2023 Financial Results.

8 months ago - Business Wire

Ligand To Report Second Quarter 2023 Financial Results On August 8

SAN DIEGO--(BUSINESS WIRE)-- #earnings--Ligand To Report Second Quarter 2023 Financial Results On August 8.

9 months ago - Business Wire